Milestone in Rare Disease Treatment Omaveloxolone Approved by MHRA

United kingdom, On April 23: MHRA Grants Approval to First-Ever UK Treatment for Friedreich’s Ataxia The Medicines and Healthcare products Regulatory Agency (MHRA) has approved omaveloxolone (sold under the name Skyclarys), making it the first licensed therapy in the UK for patients aged 16 and over with Friedreich’s ataxia, a rare inherited neurological disorder. Friedreich’s ataxia, the most prevalent genetic form of ataxia, impacts about one in 50,000 people and leads to a progressive decline in coordination and motor control. Skyclarys is administered in the form of an oral capsule.

In an official press release of the Medicines and Healthcare products Regulatory Agency, Julian Beach, MHRA Interim Executive Director of Healthcare Quality and Access, said: “Patient safety is our top priority. I am pleased to confirm the first UK approval for the treatment of Friedreich’s ataxia, omaveloxolone. We’re assured that the appropriate regulatory standards of safety, quality and effectiveness for the approval of this new treatment have been met. As with all products, we will keep its safety under close review.”

Individuals with Friedreich’s ataxia tend to have lower levels and reduced activity of a protein known as Nrf2, which plays a crucial role in protecting cells from oxidative stress, a harmful condition that arises when the body has an imbalance between free radicals and antioxidants, potentially leading to cell and tissue damage. Omaveloxolone works by activating the Nrf2 pathway.

In a clinical study, participants who received omaveloxolone demonstrated improvements in neurological function compared to those who received a placebo. The trial included 103 individuals between the ages of 16 and 40 diagnosed with Friedreich’s ataxia. After 48 weeks of treatment, those given omaveloxolone showed greater improvement in physical abilities than those in the placebo group.

The approval of omaveloxolone (Skyclarys) marks a significant milestone in the treatment of Friedreich’s ataxia in the UK, offering new hope for patients aged 16 and over living with this rare, progressive neurological disorder. Backed by clinical trial evidence and regulatory assurance of its safety and effectiveness, this first-of-its-kind therapy provides a targeted approach by activating the Nrf2 pathway to help manage symptoms and slow physical decline. With ongoing safety monitoring in place, Skyclarys represents a promising advancement in the care of individuals affected by this debilitating condition.